The protocol: Influence of the combination carriage CYP2C19*2 and *17 on efficacy of clopidogrel

E. M. Zelenskaya, O. L. Barbarash, V. I. Ganyukov, N. A. Kochergin, K. A. Apartsin, A. V. Gorokhova, S. A. Papeshina, K. Yu Nikolaev, K. Yu Batueva, S. V. Yankovskaya, O. V. Tronin, G. I. Lifshits

    Research output: Contribution to journalArticlepeer-review


    Aim. To assess the association of efficacy and safety endpoints with simultaneous carriage of polymorphic variants of the gene CYP2C19: rs4244285 (*2), and rs12248560 (*17) in treatment with clopidogrel. Material and methods. In the study, 289 patients included, from large cities of Siberia, underwent coronary stenting for acute coronary syndrome. All participants were assessed for alleles CYP2C19*2, *3, *17, and clinical outcomes were followed for 30 days (thrombotic complications, bleedings). Results. It was found that simultaneous carriage of CYP2C19*2 and CYP2C19*17 alleles is associated with the risk of serious adverse events development of thrombotic origin comparing to the absence of such polymorphism carriage (p=0,016), and with general adverse events risk related to insufficiency of clopidogrel action (p=0,046). Conclusion. According to the study results, subjects with the *2/*17 carriage should be classified to a delayed clopidogrel metabolism group, as in the group definite and probable stent thrombosis were found significantly more prevalent.

    Original languageEnglish
    Pages (from-to)113-117
    Number of pages5
    JournalRussian Journal of Cardiology
    Issue number10
    Publication statusPublished - 2017


    • Clopidogrel
    • CYP2C19
    • Stent thrombosis


    Dive into the research topics of 'The protocol: Influence of the combination carriage CYP2C19*2 and *17 on efficacy of clopidogrel'. Together they form a unique fingerprint.

    Cite this